India’s Life Sciences Sector at a Turning Point: Can Innovation Scale Globally?

Introduction

India’s life sciences sector has long been recognized as a powerhouse of generic drug manufacturing, but a new report suggests it is at a pivotal moment in its evolution toward becoming a center of original innovation. Over the past decade, the country has produced several first-in-class drugs, indigenous CAR-T therapies, and AI-discovered molecules. Yet, according to a joint report by Boston Consulting Group (BCG) and HealthKois, significant structural barriers prevent these early successes from scaling into a sustained innovation engine.

Background

The report, titled "India’s Pharma and Life Sciences Innovation Opportunity," analyzes the sector’s progress from 2016 to 2026. Key metrics show patent filings increased more than fourfold, innovation pipeline assets grew by 1.5 times, biotech startups rose by 1.6 times, and private capital for healthcare innovation increased sharply. Notable achievements include Wockhardt’s intravenous antibiotic Zaynich (cefepime-zidebactam), which received FDA approval in June 2026 for complicated urinary tract infections, and Pandorum Technologies’ $18 million Series B round for exosome-based therapies.

Main Analysis

Despite these milestones, the report emphasizes that India’s innovation story remains "early and uneven." Momentum is concentrated in late-stage translation, while early-stage research, clinical execution, regulatory consistency, and early-stage capital access lag behind. For instance, maximum public grant sizes in India are around $52,000, compared to $2–3 million in the U.S. and EU. Clinical trial approval times average 90 days in India versus 30 days in the U.S. Additionally, Indian venture capital firms exhibit low risk appetite for biotech, and the country lacks high-quality local suppliers for research-grade raw materials—especially for advanced modalities like gene therapy—leading to 30–45 day import lead times.

Global Perspective

India’s challenges mirror those of many emerging economies striving to transition from manufacturing to innovation. However, its large pool of scientific talent, relatively low costs, and growing digital infrastructure give it a unique advantage. If India can address its structural gaps, it could lower global drug costs, especially for biologics and cell therapies. For example, indigenous CAR-T therapies already treat patients at a fraction of global costs. The country’s success would also diversify global R&D supply chains, reducing dependence on a few innovation hubs.

Key Insights

• Funding Mismatch: Early-stage biotech in India suffers from a lack of specialist capital. Most venture funds prefer lower-risk IT investments. Building a first generation of dedicated biotech funds is critical.
• Academic-Industry Bridges: Stronger partnerships between universities and pharmaceutical companies can accelerate translation. Current incentives for collaboration are weak.
• Regulatory Streamlining: Fast-track pathways for novel therapies, similar to the U.S. FDA’s breakthrough therapy designation, could reduce time-to-market.
• Domestic Supply Chain: Developing local suppliers for reagents, cell lines, and other materials would cut lead times and costs.
• Talent Development: While India produces many STEM graduates, quality gaps remain in specialized R&D skills. Targeted training and global mobility programs could help.

Future Outlook (2026–2036)

Over the next decade, India’s life sciences sector could follow one of two paths. If structural reforms are implemented—such as increased public funding, regulatory harmonization, and specialized venture capital—the country could become a top-five global hub for novel drug discovery. Key areas to watch include gene therapy, AI-driven drug design, and RNA therapeutics. Conversely, if gaps persist, India may remain a low-cost manufacturing base while losing its brightest talent to other innovation centers. The report’s authors are cautiously optimistic, noting that "capital that understands the science and is willing to back it through the early, uncertain years will be the difference between a handful of breakout successes and a durable innovation engine."

Conclusion

India’s life sciences sector stands at a genuine turning point. The raw ingredients for innovation are present—scientific talent, entrepreneurial energy, and demonstrated early successes. But scaling those successes requires deliberate policy action, patient capital, and ecosystem-wide collaboration. For the global community, the stakes are high: a thriving Indian life sciences sector could mean more affordable therapies for millions, diversified drug supplies, and a more inclusive model of biomedical innovation.

---

This article is based on a report by Boston Consulting Group and HealthKois.